Vienna Diabetes Day, 5 April 2022
This year, the scientific direction of Vienna Diabetes Day was led by the dedicated diabetes experts Priv.-Doz. Dr Johanna Brix (Landstraße Clinic) and Priv.-Doz. Dr Gersina Rega-Kaun (Ottakring Clinic).
We asked them what new developments in medication diabetes patients can expect in the near future.
Priv.-Doz. Dr Johanna Brix: We now have these GLP-1 receptor agonists as standard therapy, where we are already seeing a good reduction in HbA1c and also weight loss; however, for next year, to see these used in combination with a second gut hormone, where we expect an HbA1c reduction of up to 2.4 per cent and a weight loss of up to 20 per cent of body weight – these would be dramatic changes, and these are very potent medicines that we are actually very much looking forward to.
Priv.-Doz. Dr Gersina Rega-Kaun: Then there are also insulins on the way that are likely to be effective for longer; for instance, we’ll have an insulin that only needs to be injected once a week. This would be ideal, for example, for someone in a care home or at home with a carer, where one might say that a basal insulin – you might not need to achieve an HbA1c of, say, 7, but would be happy with 7.5, because otherwise many patients would have had high levels of multimorbidity, and in such cases we could administer a long-acting insulin.